Last reviewed · How we verify
EXS21546 Powder for Oral Suspension
EXS21546 Powder for Oral Suspension is a Small molecule drug developed by Exscientia AI Limited. It is currently in Phase 1 development.
At a glance
| Generic name | EXS21546 Powder for Oral Suspension |
|---|---|
| Sponsor | Exscientia AI Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- 3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EXS21546 Powder for Oral Suspension CI brief — competitive landscape report
- EXS21546 Powder for Oral Suspension updates RSS · CI watch RSS
- Exscientia AI Limited portfolio CI
Frequently asked questions about EXS21546 Powder for Oral Suspension
What is EXS21546 Powder for Oral Suspension?
EXS21546 Powder for Oral Suspension is a Small molecule drug developed by Exscientia AI Limited.
Who makes EXS21546 Powder for Oral Suspension?
EXS21546 Powder for Oral Suspension is developed by Exscientia AI Limited (see full Exscientia AI Limited pipeline at /company/exscientia-ai-limited).
What development phase is EXS21546 Powder for Oral Suspension in?
EXS21546 Powder for Oral Suspension is in Phase 1.